Actuate Therapeutics (ACTU) vs Lipocine (LPCN)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Lipocine (LPCN) has outperformed Actuate Therapeutics (ACTU) over the past year, losing 31.7% versus a loss of 89.7%. Lipocine is the larger company by market cap ($18.1 million vs $17.4 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ACTU | LPCN |
|---|---|---|
| Share price | $0.7242 | $2.20 |
| Market cap | $17.39M | $18.14M |
| 1-day change | -10.77% | +4.76% |
| YTD return | -88.17% | -72.60% |
| 1-year return | -89.71% | -31.68% |
| 5-year return | — | -88.55% |
| EPS (TTM) | $-0.77 | $-1.85 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $8.49 | $12.37 |
| 52-week low | $0.604 | $1.81 |
| Distance from 52-week high | -91.47% | -82.22% |
| Average volume | 387.90K | 35.40K |
| Shares outstanding | 24.01M | 8.24M |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- LPCN has outperformed ACTU by 58.0 percentage points over the past year.
ACTU vs LPCN FAQ
Which is bigger, Actuate Therapeutics or Lipocine?
Lipocine (LPCN) is larger, with a market capitalization of $18.14M compared with $17.39M for Actuate Therapeutics (ACTU).
Which stock has performed better over the past year, ACTU or LPCN?
LPCN returned -31.68% over the past 12 months, compared with -89.71% for ACTU (price return, excluding dividends). Past performance does not predict future results.
Are Actuate Therapeutics and Lipocine in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.